Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23786836 | 0.88 | THRB (0.51) | THRBALDH1A1TP53CYP3A4MAPK1 | |
| SCHEMBL12403197 | 0.85 | THRB (0.48) | THRBALDH1A1TP53CYP3A4MAPK1 | |
| SCHEMBL18016196 | 0.84 | THRB (0.50) | THRBALDH1A1TP53CYP3A4MAPK1 | |
| SCHEMBL19500475 | 0.83 | THRB (0.56) | THRBALDH1A1TP53CYP3A4MAPK1 | |
| SCHEMBL12928839 | 0.83 | THRB (0.56) | THRBALDH1A1TP53CYP3A4MAPK1 | |
| SCHEMBL13227927 | 0.80 | THRB (0.51) | THRBALDH1A1TP53CYP3A4MAPK1 | |
| SCHEMBL12403180 | 0.80 | — | — | |
| SCHEMBL18017139 | 0.79 | THRB (0.45) | THRBALDH1A1TP53CYP3A4MAPK1 | |
| SCHEMBL19509861 | 0.79 | THRB (0.51) | THRBALDH1A1TP53CYP3A4MAPK1 | |
| SCHEMBL19500479 | 0.79 | THRB (0.62) | THRBALDH1A1TP53CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985424-B2 | Dendritic polymers with enhanced amplification and interior functionality | DENDRITIC NANOTECHNOLOGIES INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-7985424-B2 | Dendritic polymers with enhanced amplification and interior functionality | DENDRITIC NANOTECHNOLOGIES INC. (US) | 2011-07-26 | — | — | US | disclosed |
| EP-2325236-A1 | Dendritic polymers with enhanced amplification and interior functionality | Dendritic Nanotechnologies Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20070298006-A1 | Dendritic Polymers With Enhanced Amplification and Interior Functionality | DENDRITIC NANOTECHNOLOGIES, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070298006-A1 | Dendritic Polymers With Enhanced Amplification and Interior Functionality | DENDRITIC NANOTECHNOLOGIES, INC. (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070298006-A1 | Dendritic Polymers With Enhanced Amplification and Interior Functionality | MYD88, TLR3, TMEM97 | THRB 3966/4885ALDH1A1 2720/4885TP53 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.